Page last updated: 2024-10-31

midodrine and Neurally Mediated Faint

midodrine has been researched along with Neurally Mediated Faint in 45 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Research Excerpts

ExcerptRelevanceReference
" All studies were conducted in clinical syncope populations and compared the benefit of midodrine vs."9.22Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis. ( Lei, LY; Raj, SR; Sheldon, RS, 2022)
" All studies were conducted in clinical syncope populations and compared the benefit of midodrine vs."5.22Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis. ( Lei, LY; Raj, SR; Sheldon, RS, 2022)
" After one week the dosage will be up-titrated to midodrine 30 mg/day and fludrocortisone 0."3.01Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. ( Akbarzadeh, MA; Alaeddini, F; Aminorroaya, A; Apakuppakul, S; Ariannejad, H; Bozorgi, A; Emkanjoo, Z; Jalali, A; Joharimoghadam, A; Kiarsi, M; Mohammadi, R; Mohsenizade, A; Mollazadeh, R; Ngarmukos, T; Oraii, A; Oraii, S; Rahimi, B; Sadeghian, S; Shahabi, J; Tajdini, M; Tavolinejad, H, 2021)
"Recurrent vasovagal syncope is common, responds poorly to treatment, and causes physical trauma and poor quality of life."3.01Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial. ( Ayala-Paredes, F; Faris, P; Guzman, J; Krahn, AD; Kus, T; Marquez, M; Maxey, C; Morillo, CA; Raj, SR; Ritchie, D; Safdar, S; Sheldon, R; Tang, A, 2021)
"Midodrine is a pro-drug whose primary metabolite is an alpha-1 adrenoreceptor agonist."2.77Rationale for the prevention of syncope trial IV: assessment of midodrine. ( Faris, PD; McRae, M; Raj, SR; Sheldon, RS, 2012)
"Initial treatment of vasovagal syncope (VVS) consists of advising adequate fluid and salt intake, regular exercise, and physical counterpressure manoeuvres."2.76Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). ( Go-Schön, IK; Reitsma, JB; Romme, JJ; van Dijk, N; Wieling, W, 2011)
"Midodrine is an alpha-agonist prodrug of desglymidodrine (DGM) that has been reported to be of clinical benefit in patients with neurocardiogenic syncope."2.73Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study. ( Champlain, Jd; Lamarre-Cliche, M; Larochelle, P; Souich, Pd, 2008)
"Treatment with atenolol, midodrine and their combination prevented VVS in 89% patients."2.72[Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes]. ( Al'bitskaia, KV; Golitsyn, SP; Kheĭmets, GI; Kuchinskaia, EA; Pevzner, AV; Rogoza, AN; Vershuta, EV, 2006)
"Midodrine was given at a starting dose of 5 mg three times a day and increased up to a dose of 15 mg three times a day when required."2.70Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. ( Akhtar, M; Bash, D; Beheiry, S; Jaeger, F; Leonelli, FM; Natale, A; Pavia, S; Perez-Lugones, A; Saliba, W; Schweikert, R; Shewchik, J; Sra, J; Tchou, PJ; Tomassoni, GF, 2001)
"Therapy of vasovagal syncope is still a subject of debate."2.69Midodrine hydrochloride in the treatment of vasovagal syncope. ( Mitro, P; Rybár, AR; Trejbal, D, 1999)
"Syncope is a common symptom and accounts for approximately 1% of all emergency visits."2.46Evaluation and management of syncope. ( Borggrefe, M; Schimpf, R; Veltmann, C; Wolpert, C, 2010)
"Vasovagal syncope is a common disorder of autonomic cardiovascular regulation."2.40Pharmacologic approaches to therapy for vasovagal syncope. ( Calkins, H, 1999)
"In the OI spectrum, postural tachycardia syndrome (POTS) accounted for 826 cases (39."1.72[A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children]. ( Chen, YH; Cui, YX; DU, JB; Jin, HF; Liao, Y; Liu, P; Liu, XQ; Qi, JG; Sun, CF; Sun, Y; Wang, YL; Xu, WR; Yan, H; Zhang, CY; Zhang, QY, 2022)
"Vasovagal syncope is the most common cause of syncope in childhood and its treatment is not at a satisfactory level yet."1.62Midodrine treatment in children with recurrent vasovagal syncope. ( Atik, F; Bagrul, D; Ece, I; Kavurt, AV; Yılmaz, A, 2021)
"Pirmenol treatment was not associated with syncope during ordinary HUT, but nausea, sweating, and syncope occurred during HUT with provocative administration of isosorbide dinitrate."1.32A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy. ( Emi, S; Ishimoto, T; Kageyama, N; Mizuguchi, Y; Nagase, N; Oishi, Y; Oki, T, 2004)
"Midodrine was initially administered orally at a dose of 2."1.30Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. ( Akhtar, M; Biehl, M; Blanck, Z; Deshpande, S; Dhala, A; Jazayeri, MR; Maglio, C; Sra, J, 1997)
"Pharmacological therapy of neurocardiogenic syncope is often limited by the relatively low response rate to such treatment."1.30Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers. ( Credner, S; Hohnloser, SH; Klingenheben, T, 1999)

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (15.56)18.2507
2000's18 (40.00)29.6817
2010's8 (17.78)24.3611
2020's12 (26.67)2.80

Authors

AuthorsStudies
Thorens, A1
Lei, LY1
Raj, SR3
Sheldon, RS4
Shaughnessy, AF1
Gerber, C1
Hatoum, T1
Raj, S1
Cui, YX1
DU, JB1
Zhang, QY1
Liao, Y2
Liu, P1
Wang, YL1
Qi, JG1
Yan, H1
Xu, WR1
Liu, XQ1
Sun, Y1
Sun, CF1
Zhang, CY1
Chen, YH1
Jin, HF1
Behnoush, AH2
Yazdani, K2
Khalaji, A2
Tavolinejad, H3
Aminorroaya, A3
Jalali, A3
Tajdini, M3
Cannom, DS1
Bagrul, D1
Ece, I1
Yılmaz, A1
Atik, F1
Kavurt, AV1
Sadeghian, S1
Alaeddini, F1
Emkanjoo, Z1
Mollazadeh, R1
Bozorgi, A1
Oraii, S1
Kiarsi, M1
Shahabi, J1
Akbarzadeh, MA1
Rahimi, B1
Joharimoghadam, A1
Mohsenizade, A1
Mohammadi, R1
Oraii, A1
Ariannejad, H1
Apakuppakul, S1
Ngarmukos, T1
Brignole, M1
Sheldon, R1
Faris, P1
Tang, A1
Ayala-Paredes, F1
Guzman, J1
Marquez, M1
Morillo, CA1
Krahn, AD1
Kus, T1
Ritchie, D1
Safdar, S1
Maxey, C1
Hutt Centeno, E1
Mayuga, KA1
Li, Y1
Li, H1
Li, X3
Jin, H1
Lamarre-Cliche, M1
Souich, Pd1
Champlain, Jd1
Larochelle, P1
Kuriachan, V1
Platonov, M1
Zhang, Y1
Chen, S1
Tang, C1
Du, J1
Liu, XY1
Wang, C1
Wu, LJ1
Hu, CY1
Lin, P1
Li, MX1
Cui, XL1
Xie, ZW1
Paling, D1
Vilches-Moraga, A1
Akram, Q1
Atkinson, O1
Staniland, JR1
Paredes-Galán, E1
Veltmann, C1
Borggrefe, M1
Wolpert, C1
Schimpf, R1
Romme, JJ1
van Dijk, N1
Go-Schön, IK1
Reitsma, JB1
Wieling, W1
Oz, F1
Cizgici, Y1
Bilge, AK1
Faris, PD1
McRae, M1
Kaufmann, H1
Saadia, D1
Voustianiouk, A1
Kuchinskaia, EA3
Pevzner, AV3
Vershuta, EV3
Al'bitskaia, KV3
Kheĭmets, GI2
Rogoza, AN3
Golitsyn, SP3
Kheĭmetz, GI1
Tripoten', MI1
Mizuguchi, Y1
Ishimoto, T1
Kageyama, N1
Oishi, Y1
Emi, S1
Nagase, N1
Oki, T1
Chen, LY1
Shen, WK1
Gracie, J1
Newton, JL1
Norton, M1
Baker, C1
Freeston, M1
Stewart, JM1
Qingyou, Z1
Junbao, D1
Chaoshu, T1
Amaki, M1
Kamide, K1
Takiuchi, S1
Niizuma, S1
Horio, T1
Kawano, Y1
Sra, J2
Maglio, C1
Biehl, M1
Dhala, A1
Blanck, Z1
Deshpande, S1
Jazayeri, MR1
Akhtar, M2
Ward, CR1
Gray, JC1
Gilroy, JJ1
Kenny, RA1
Klingenheben, T1
Credner, S1
Hohnloser, SH1
Dubin, AM1
Van Hare, GF1
Calkins, H1
Mitro, P1
Trejbal, D1
Rybár, AR1
Samniah, N2
Iskos, D2
Sakaguchi, S2
Lurie, KG2
Benditt, DG2
Perez-Lugones, A1
Schweikert, R1
Pavia, S1
Jaeger, F1
Tomassoni, GF1
Saliba, W1
Leonelli, FM1
Bash, D1
Beheiry, S1
Shewchik, J1
Tchou, PJ1
Natale, A1
Low, PA1
Wiley, TM1
Luu, VD1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Compression Stockings for Treating Vasovagal Syncope (COMFORTS II) Trial; a Double Blind, Multi-center Randomized Controlled Trial[NCT05086679]268 participants (Anticipated)Interventional2022-03-14Recruiting
Comparison of Outcomes With Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS Trial)[NCT04595942]Phase 31,375 participants (Anticipated)Interventional2020-11-19Recruiting
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4)[NCT01456481]Phase 4134 participants (Actual)Interventional2011-11-30Active, not recruiting
Effect of Cardioneuroablation vs Midodrine on Syncope Recurrence Among Patients With Vasovagal Syncope: The CAMPAIGN Randomized Clinical Trial[NCT05803148]184 participants (Anticipated)Interventional2023-04-05Recruiting
CardioneuROablation for Reflex Syncope: Effects on autonoMic cArdiac Regulation and Efficacy Assessment - the Roman Syncope Study.[NCT03903744]48 participants (Actual)Interventional2018-11-01Completed
A Pilot Study to Assess Sinusoidal Galvanic Vestibular Stimulation in Neurogenic Orthostatic Hypotension[NCT04976101]0 participants (Actual)Interventional2023-01-01Withdrawn (stopped due to It never enrolled any patients)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

9 reviews available for midodrine and Neurally Mediated Faint

ArticleYear
Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2022, 07-21, Volume: 24, Issue:7

    Topics: Double-Blind Method; Female; Humans; Male; Midodrine; Randomized Controlled Trials as Topic; Syncope

2022
Current approach to the treatment of vasovagal syncope in adults.
    Internal and emergency medicine, 2023, Volume: 18, Issue:1

    Topics: Adult; Aged; Humans; Midodrine; Quality of Life; Randomized Controlled Trials as Topic; Syncope, Vas

2023
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
    Heart rhythm, 2023, Volume: 20, Issue:3

    Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope

2023
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
    Heart rhythm, 2023, Volume: 20, Issue:3

    Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope

2023
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
    Heart rhythm, 2023, Volume: 20, Issue:3

    Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope

2023
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
    Heart rhythm, 2023, Volume: 20, Issue:3

    Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope

2023
Evidence-based treatment for vasovagal syncope.
    Heart rhythm, 2008, Volume: 5, Issue:11

    Topics: Evidence-Based Medicine; Fludrocortisone; Humans; Midodrine; Pacemaker, Artificial; Selective Seroto

2008
alpha-Adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data.
    Acta paediatrica (Oslo, Norway : 1992), 2009, Volume: 98, Issue:7

    Topics: Adrenergic alpha-Agonists; Etilefrine; Humans; Midodrine; Outcome Assessment, Health Care; Randomize

2009
Evaluation and management of syncope.
    Minerva cardioangiologica, 2010, Volume: 58, Issue:6

    Topics: Diagnosis, Differential; Electrocardiography; Humans; Hypotension, Orthostatic; Midodrine; Practice

2010
Neurocardiogenic syncope: latest pharmacological therapies.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Fluoxetine; Heart

2006
Advances in the treatment of cardiac rhythm disturbances.
    Current opinion in pediatrics, 1999, Volume: 11, Issue:5

    Topics: Adrenergic alpha-Agonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Electrophysiolog

1999
Pharmacologic approaches to therapy for vasovagal syncope.
    The American journal of cardiology, 1999, Oct-21, Volume: 84, Issue:8A

    Topics: Atenolol; Fludrocortisone; Humans; Midodrine; Paroxetine; Randomized Controlled Trials as Topic; Syn

1999

Trials

14 trials available for midodrine and Neurally Mediated Faint

ArticleYear
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
    American heart journal, 2021, Volume: 237

    Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor

2021
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
    American heart journal, 2021, Volume: 237

    Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor

2021
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
    American heart journal, 2021, Volume: 237

    Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor

2021
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
    American heart journal, 2021, Volume: 237

    Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor

2021
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
    Annals of internal medicine, 2021, Volume: 174, Issue:10

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age

2021
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
    Annals of internal medicine, 2021, Volume: 174, Issue:10

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age

2021
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
    Annals of internal medicine, 2021, Volume: 174, Issue:10

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age

2021
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
    Annals of internal medicine, 2021, Volume: 174, Issue:10

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age

2021
Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study.
    Clinical therapeutics, 2008, Volume: 30, Issue:9

    Topics: Adult; Autonomic Nervous System; Blood Pressure; Chromatography, High Pressure Liquid; Cross-Over St

2008
[Efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope].
    Zhonghua yi xue za zhi, 2009, Jul-28, Volume: 89, Issue:28

    Topics: Adolescent; Child; Female; Follow-Up Studies; Humans; Male; Midodrine; Syncope, Vasovagal; Tilt-Tabl

2009
Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial).
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:11

    Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Cross-Over Studies; Double-Blind Method; Exercise; Fema

2011
Rationale for the prevention of syncope trial IV: assessment of midodrine.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2012, Volume: 22, Issue:6

    Topics: Adrenergic alpha-1 Receptor Agonists; Humans; Intention to Treat Analysis; Midodrine; Multicenter St

2012
Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study.
    Annals of neurology, 2002, Volume: 52, Issue:3

    Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hypotens

2002
[Results of midodrin treatment of vasovagal syncope].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:8

    Topics: Adolescent; Adult; Aged; Drug Tolerance; Female; Humans; Male; Middle Aged; Midodrine; Syncope, Vaso

2004
[Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes].
    Terapevticheskii arkhiv, 2006, Volume: 78, Issue:4

    Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Drug Ther

2006
The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope.
    The Journal of pediatrics, 2006, Volume: 149, Issue:6

    Topics: Adolescent; Adrenergic alpha-Agonists; Child; Female; Humans; Male; Midodrine; Syncope, Vasovagal

2006
Midodrine: a role in the management of neurocardiogenic syncope.
    Heart (British Cardiac Society), 1998, Volume: 79, Issue:1

    Topics: Adrenergic alpha-Agonists; Blood Pressure; Cardiography, Impedance; Cross-Over Studies; Double-Blind

1998
Midodrine hydrochloride in the treatment of vasovagal syncope.
    Pacing and clinical electrophysiology : PACE, 1999, Volume: 22, Issue:11

    Topics: Adrenergic alpha-Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; F

1999
Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope.
    The American journal of cardiology, 2001, Jul-01, Volume: 88, Issue:1

    Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Age

2001
Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study.
    Journal of cardiovascular electrophysiology, 2001, Volume: 12, Issue:8

    Topics: Adrenergic alpha-Agonists; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human

2001

Other Studies

22 other studies available for midodrine and Neurally Mediated Faint

ArticleYear
    Revue medicale suisse, 2021, Nov-10, Volume: 17, Issue:758

    Topics: Humans; Midodrine; Syncope, Vasovagal; Treatment Outcome

2021
Midodrine Is Worth a Trial in People With Frequent Episodes of Vasovagal Syncope.
    American family physician, 2022, 04-01, Volume: 105, Issue:4

    Topics: Humans; Midodrine; Recurrence; Syncope, Vasovagal

2022
    Revue medicale suisse, 2022, 04-27, Volume: 18, Issue:779

    Topics: Health Status; Humans; Midodrine; Quality of Life; Syncope, Vasovagal; Treatment Outcome

2022
[A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2022, Oct-18, Volume: 54, Issue:5

    Topics: Child; Electrolytes; Female; Humans; Male; Metoprolol; Midodrine; Orthostatic Intolerance; Postural

2022
Management of coexistent neurogenic orthostatic hypotension and supine hypertension.
    Journal of clinical hypertension (Greenwich, Conn.), 2019, Volume: 21, Issue:11

    Topics: Accidental Falls; Central Nervous System Agents; Droxidopa; Drug Substitution; Female; Humans; Hyper

2019
Midodrine treatment in children with recurrent vasovagal syncope.
    Cardiology in the young, 2021, Volume: 31, Issue:5

    Topics: Adolescent; Child; Humans; Midodrine; Recurrence; Retrospective Studies; Syncope, Vasovagal

2021
Establishing the Efficacy of Midodrine to Prevent Vasovagal Syncope.
    Annals of internal medicine, 2021, Volume: 174, Issue:10

    Topics: Humans; Midodrine; Syncope, Vasovagal

2021
Summary for Patients: Midodrine to Prevent Fainting.
    Annals of internal medicine, 2021, Volume: 174, Issue:10

    Topics: Adult; Humans; Midodrine; Syncope, Vasovagal; Vasoconstrictor Agents

2021
What can I do when first-line measures are not enough for vasovagal syncope?
    Cleveland Clinic journal of medicine, 2018, Volume: 85, Issue:12

    Topics: Adrenergic beta-Antagonists; Adult; Combined Modality Therapy; Female; Fludrocortisone; Head-Down Ti

2018
Prognostic analysis of orthostatic intolerance using survival model in children.
    Chinese medical journal, 2014, Volume: 127, Issue:21

    Topics: Adolescent; Child; Female; Humans; Male; Metoprolol; Midodrine; Orthostatic Intolerance; Prognosis;

2014
Midodrine hydrochloride is safe and effective in older people with neurocardiogenic syncope.
    Journal of the American Geriatrics Society, 2010, Volume: 58, Issue:10

    Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow

2010
A patient treated with tilt training and midodrine after 68 seconds asystole during head-up tilt table testing.
    Acta cardiologica, 2011, Volume: 66, Issue:4

    Topics: Combined Modality Therapy; Electrocardiography; Heart Arrest; Humans; Male; Midodrine; Physical Ther

2011
[Successful midodrin treatment for vasovagal syncopes accompanied by asystole].
    Klinicheskaia meditsina, 2004, Volume: 82, Issue:9

    Topics: Adrenergic alpha-Agonists; Adult; Atropine; Electrocardiography; Heart Arrest; Heart Massage; Humans

2004
A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:5

    Topics: Aged; Anti-Arrhythmia Agents; Humans; Male; Midodrine; Piperidines; Prostatic Hyperplasia; Syncope,

2004
The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2006, Volume: 8, Issue:8

    Topics: Adaptation, Psychological; Adult; Aged; Anxiety; Cross-Sectional Studies; Depression; Fear; Female;

2006
Midodrine for the treatment of vasovagal syncope (simple faint).
    The Journal of pediatrics, 2006, Volume: 149, Issue:6

    Topics: Child; Humans; Midodrine; Syncope, Vasovagal

2006
A case of neurally mediated syncope induced by laughter successfully treated with combination of propranolol and midodrine.
    International heart journal, 2007, Volume: 48, Issue:1

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Drug Therapy, Combination; Electrocard

2007
Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy.
    Journal of cardiovascular electrophysiology, 1997, Volume: 8, Issue:1

    Topics: Administration, Oral; Adult; Drug Tolerance; Female; Humans; Male; Middle Aged; Midodrine; Sympathom

1997
Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.
    Pacing and clinical electrophysiology : PACE, 1999, Volume: 22, Issue:2

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Clinical Protocols; Female; Follow-Up Studie

1999
Syncope in pharmacologically unmasked Brugada syndrome: indication for an implantable defibrillator or an unresolved dilemma?
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2001, Volume: 3, Issue:2

    Topics: Adult; Bundle-Branch Block; Defibrillators, Implantable; Diagnosis, Differential; Electrocardiograph

2001
Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction.
    Neurology, 1995, Volume: 45, Issue:4 Suppl 5

    Topics: Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Multicenter Studies as Topic;

1995
Recurrent syncope in a 31-year-old army staff sergeant.
    Military medicine, 2002, Volume: 167, Issue:3

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Case Management; Humans; Ma

2002